Skip to content

Study · Observational study · n = 20,538 · 2025

4 results

Comparative clinical outcomes of adults with obstructive sleep apnea and comorbid obesity receiving tirzepatide versus bariatric metabolic surgery: A Multi-Institutional propensity score matched study.

Wu JY, Lin YM, Hsu WH, Liu TH, Tsai YW, Huang PY, Chuang MH, Yu T, Lai CC

Diabetes research and clinical practice31 May 2025Cited by 3 (Europe PMC)

PMID40456414 (opens in a new tab)DOI10.1016/j.diabres.2025.112294 (opens in a new tab)PepBankPUB-40456414
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with obstructive sleep apnea and obesity, tirzepatide and bariatric metabolic surgery did not differ significantly in the primary composite of mortality, MACE and MAKE.

    In plain wordsIn adults with sleep apnea and obesity, tirzepatide and weight-loss surgery had no clear difference in deaths, heart events and kidney events combined.

    Peptide
    Tirzepatide
    Outcome
    No significant changeComposite of all-cause mortality, MACE and MAKE
    Study

    n = 20,538

    Comparator
    Bariatric metabolic surgery
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.87 ratio
    tirzepatide vs BMS, primary composite

    Source sentences

    Summary
    No significant difference was observed between groups for the primary composite outcome (hazard ratio [HR], 0.87; 95 % CI, 0.66-1.15, p = 0.335).
    2 context sentences
    Summary · context
    A retrospective cohort analysis was conducted using the TriNetX Global Collaborative Network.
    Summary · context
    Following PSM, each 10,269 patients with well-balanced characteristics were classified into the tirzepatide and BMS groups.
  2. 02HumanObservational studyEfficacy outcome

    In adults with obstructive sleep apnea and obesity, all-cause mortality did not differ significantly between tirzepatide and bariatric metabolic surgery.

    In plain wordsIn adults with sleep apnea and obesity, tirzepatide and weight-loss surgery showed no clear difference in deaths.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAll-cause mortality
    Study

    n = 20,538

    Comparator
    Bariatric metabolic surgery
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.9 ratio
    tirzepatide vs BMS, all-cause mortality

    Source sentences

    Summary
    all-cause mortality (HR, 0.90; 95 % CI, 0.56-1.46, p = 0.672)
    2 context sentences
    Summary · context
    A retrospective cohort analysis was conducted using the TriNetX Global Collaborative Network.
    Summary · context
    Following PSM, each 10,269 patients with well-balanced characteristics were classified into the tirzepatide and BMS groups.
  3. 03HumanObservational studyEfficacy outcome

    In adults with obstructive sleep apnea and obesity, MACE did not differ significantly between tirzepatide and bariatric metabolic surgery.

    In plain wordsIn adults with sleep apnea and obesity, tirzepatide and weight-loss surgery showed no clear difference in major heart events.

    Peptide
    Tirzepatide
    Outcome
    No significant changeMajor adverse cardiovascular events (MACE)
    Study

    n = 20,538

    Comparator
    Bariatric metabolic surgery
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    1.16 ratio
    tirzepatide vs BMS, MACE

    Source sentences

    Summary
    MACE (HR, 1.16; 95 % CI 0.85-1.56, p = 0.344)
    2 context sentences
    Summary · context
    A retrospective cohort analysis was conducted using the TriNetX Global Collaborative Network.
    Summary · context
    Following PSM, each 10,269 patients with well-balanced characteristics were classified into the tirzepatide and BMS groups.
  4. 04HumanObservational studyEfficacy outcome

    In adults with obstructive sleep apnea and obesity, tirzepatide was associated with a lower rate of MAKE than bariatric metabolic surgery.

    In plain wordsIn adults with sleep apnea and obesity, tirzepatide was linked to fewer major kidney events than weight-loss surgery.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMajor adverse kidney events (MAKE)
    Study

    n = 20,538

    Comparator
    Bariatric metabolic surgery
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.6 ratio
    tirzepatide vs BMS, MAKE

    Source sentences

    Summary
    However, tirzepatide was associated with a lower rate of MAKE compared to BMS (HR, 0.60; 95 % CI, 0.42-0.87, p = 0.006).
    2 context sentences
    Summary · context
    A retrospective cohort analysis was conducted using the TriNetX Global Collaborative Network.
    Summary · context
    Following PSM, each 10,269 patients with well-balanced characteristics were classified into the tirzepatide and BMS groups.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.